BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38364744)

  • 1. Predictive response and outcome of peripheral CD4
    Gao D; Liu L; Liu J; Liu J
    Int Immunopharmacol; 2024 Mar; 129():111663. PubMed ID: 38364744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating memory PD-1
    Liu J; Liu D; Hu G; Wang J; Chen D; Song C; Cai Y; Zhai C; Xu W
    Cancer Cell Int; 2023 Nov; 23(1):274. PubMed ID: 37974194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral CD4
    Xia L; Wang H; Sun M; Yang Y; Yao C; He S; Duan H; Xia W; Sun R; Yao Y; Chen Z; Zhao Q; Li H; Lu S; Wang Y
    Sci China Life Sci; 2021 Oct; 64(10):1590-1601. PubMed ID: 33521853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.
    Wang X; Liu X; Dai H; Jia J
    BMC Gastroenterol; 2024 Mar; 24(1):113. PubMed ID: 38491354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.
    Ding P; Guo H; Sun C; Yang P; Kim NH; Tian Y; Liu Y; Liu P; Li Y; Zhao Q
    BMC Gastroenterol; 2022 Mar; 22(1):121. PubMed ID: 35287591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
    Zurlo IV; Schino M; Strippoli A; Calegari MA; Cocomazzi A; Cassano A; Pozzo C; Di Salvatore M; Ricci R; Barone C; Bria E; Tortora G; Larocca LM; Basso M; Martini M
    Cancer Immunol Immunother; 2022 Jan; 71(1):45-55. PubMed ID: 34009410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.
    Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P
    Front Immunol; 2022; 13():809971. PubMed ID: 35185898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical predictive value of naïve and memory T cells in advanced NSCLC.
    Zhang G; Liu A; Yang Y; Xia Y; Li W; Liu Y; Zhang J; Cui Q; Wang D; Liu X; Guo Y; Chen H; Yu J
    Front Immunol; 2022; 13():996348. PubMed ID: 36119064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
    Yan Y; Wang X; Liu C; Jia J
    BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
    Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic analysis of related factors of adverse reactions to immunotherapy in advanced gastric cancer and establishment of a nomogram model.
    He XX; Du B; Wu T; Shen H
    World J Gastrointest Oncol; 2024 Apr; 16(4):1268-1280. PubMed ID: 38660670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical significance of memory T cells and its subsets in gastric cancer.
    Zhang R; Li F; Li H; Yu J; Ren X
    Clin Transl Oncol; 2014 Mar; 16(3):257-65. PubMed ID: 23793812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of dendritic cells on immune function regulated by programmed cell death-1/programmed cell death-ligand 1 in sepsis].
    Wang Z; Xie Z; Zhao Y; Bu T; Yu A; Wang S
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Sep; 33(9):1032-1039. PubMed ID: 34839857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8
    Duchemann B; Naigeon M; Auclin E; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Desnoyer A; Danlos FX; Mezquita L; Caramella C; Marabelle A; Besse B; Chaput N
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance of Composition Changes in T-cell Subpopulations After Chemotherapy in Patients With Gastric Cancer.
    Yeo MK; Sun P; Chung C; Park JH; Kang SH; Moon HS; Sung JK; Jeong HY; Kim JS
    In Vivo; 2021; 35(4):2417-2424. PubMed ID: 34182525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of nutritional indicators with regard to the survival outcomes in patients with metastatic esophageal squamous cell carcinoma treated with camrelizumab.
    Liu J; Hu G; Zhai C; Wang J; Xu W; Xie J; Zhu W; Jiang P; Liu D
    Oncol Lett; 2023 May; 25(5):198. PubMed ID: 37113404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials.
    Duan X; Du H; Qi R; Yuan M; Shi J
    Exp Ther Med; 2023 May; 25(5):216. PubMed ID: 37123204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.